GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:26 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 4:26 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta
by Zacks Equity Research
Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer
by Zacks Equity Research
Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Novartis Gets Approval for Psoriasis Drug Cosentyx in China
by Zacks Equity Research
Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
3 Big Pharma Stocks to Add to Your Portfolio This April
by Kinjel Shah
The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Top Analyst Reports for Chevron, IBM & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), IBM (IBM) and Medtronic (MDT).
Axsome's Depression Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).
5 Cancer-Fighting Stocks to Boost Portfolio Gains
by Swarup Gupta
It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Glaxo Presents Encouraging Data on Endometrial Cancer Drug
by Zacks Equity Research
Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
by Zacks Equity Research
Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $40.03 in the latest trading session, marking a -0.12% move from the prior day.
Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?
by Zacks Equity Research
Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Top Research Reports for Microsoft, Mastercard & General Electric
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Mastercard (MA) and General Electric (GE).
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
by Zacks Equity Research
Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4
by Zacks Equity Research
Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.